Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07271186 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

Study acronym: ANCHOR-POC
StatusRecruiting
PhasePhase 2
Started2026-01-09
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Sep 24, 2027 → Oct 13, 2028
Enrollment reduced 28% 270 → 195 participants
See other at-risk trials from Regeneron

Amendment history

2026-09-08
Study Identification, Study Status, Study Description, Conditions, Study Design, Arms and Interventions, Outcome Measures, Eligibility v10
Enrollment reduced: 270 → 195 participants
Primary completion pushed: 2027-09-24 → 2028-10-13
Completion pushed: 2028-04-07 → 2028-10-13
Interventions modified
Eligibility criteria+86 characters
[...] t required treatment with systemic immunosuppressive therapy (prior or current), or a history of end-stage kidney disease requiring treatment with chronic dialysis or renalkidney transplanttransplantation Medically unstable as assessed by the investigator Hospitalization or hospitalization (ie, >24 hours) within 30 days of the screening visit NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply
Secondary endpoints15 to 13 entries
Change in totalTotal cholesterolCholesterol Change in nonNon-High-Density Lipoprotein-Cholesterol (non-HDL-C) Change in triglyceridesTriglycerides Concentration of combinedCombined ALN-ANG3 and metaboliteMetabolite(s) and evinacumab Change in concentrationConcentration of Angiopoietin-Like Protein-3 (ANGPTL-3) IncidenceOccurence of Anti-Drug Antibodies (ADAs) to ALN-ANG3 Incidence of ADAs to evinacumab Magnitude of ADAs to evinacumab
Primary endpoints1 entry, revised
Percent changeChange in Urine Albumin to Creatinine Ratio (UACR)
Study title-40 characters
Study to Assess the Effects of AngiopoietinALN-like Protein 3 (ANGPTL3) InhibitionANG3 in Adult Participants With Diabetic Kidney Disease
2026-08-07
Study Status, Contacts/Locations v9
Study sites57→58
2026-07-14
Study Status, Contacts/Locations v8
Trial sites expanded: 53 → 57 locations
2026-06-24
Study Status, Contacts/Locations v7
Study sites51→53
2026-05-19
Study Status, Contacts/Locations v6
Trial sites expanded: 47 → 51 locations
2026-04-27
Study Status, Contacts/Locations v5
Trial sites expanded: 39 → 47 locations
2026-04-15
Study Status, Contacts/Locations v4
Trial sites expanded: 29 → 39 locations
2026-03-16
Study Status, Contacts/Locations v3
Study sites24→29
2026-03-12
Study Status, Contacts/Locations v2
Study sites10→24
2026-02-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2027-06-08→2027-09-24
Completion date2027-12-08→2028-04-07
Start dateestimated 2025-12-09→confirmed 2026-01-09
Study sites0→10
2025-12-07
Original filing
Regeneron
148 trials monitored
See 16 trials at risk
Chronic Kidney Disease
1,314 trials monitored
See 54 trials at risk
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times
Trial Details
NCT Number NCT07271186
Lead Sponsor Regeneron Pharmaceuticals
Conditions Diabetic Kidney Disease (DKD)
Enrollment 195 participants
Start Date 2026-01-09
Primary Completion 2028-10-13 (estimated)
Study Completion 2028-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-09-11